SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-13-085733
Filing Date
2013-11-19
Accepted
2013-11-19 15:39:57
Documents
12
Period of Report
2013-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q a13-23001_110q.htm 10-Q 270001
2 EX-10.1 a13-23001_1ex10d1.htm EX-10.1 26619
3 EX-31.1 a13-23001_1ex31d1.htm EX-31.1 16437
4 EX-31.2 a13-23001_1ex31d2.htm EX-31.2 16321
5 EX-32.1 a13-23001_1ex32d1.htm EX-32.1 4565
6 EX-32.2 a13-23001_1ex32d2.htm EX-32.2 4575
  Complete submission text file 0001104659-13-085733.txt   1657462

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT cont-20130930.xml EX-101.INS 116037
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cont-20130930.xsd EX-101.SCH 19412
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cont-20130930_cal.xml EX-101.CAL 18309
10 XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT cont-20130930_lab.xml EX-101.LAB 231400
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cont-20130930_pre.xml EX-101.PRE 123935
12 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cont-20130930_def.xml EX-101.DEF 48951
Mailing Address 420 LEXINGTON AVENUE SUITE 2012 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2012 NEW YORK NY 10170 212-297-0020
ContraVir Pharmaceuticals, Inc. (Filer) CIK: 0001583771 (see all company filings)

IRS No.: 462783806 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-55020 | Film No.: 131229901
SIC: 2834 Pharmaceutical Preparations